Business
Positive Topline Results from a Phase 3 Trial for VGX-3100 in Cervical Dysplasia Patients Announced by ApolloBio, INOVIO's Partner in China
Positive Topline Results from a Phase 3 Trial for VGX-3100 in Cervical Dysplasia Patients Announced by ApolloBio, INOVIO's Partner in
About this update from Inovio Pharmaceuticals, Inc.
[{"type":"text","content":"Results provide important clinical evidence to support ApolloBio's future regulatory submission in China of VGX-3100, INOVIO's DNA immunotherapy candidateApolloBio's new clinical results further highlight the potential of INOVIO's DNA medicine platform to treat diseases caused by infection with various strains of the human papillomavirus (HPV), eliminating or reducing the need for surgical interventionsPLYMOUTH MEETING, Pa., May 21, 2026 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that its partner for VGX-3100 in China, ApolloBio, announced positive topline results from its pivotal Phase 3 trial of VGX-3100, INOVIO's investigational DNA immunotherapy being developed as a potential treatment for cervical dysplasia. The trial successfully met its predefined primary efficacy endpoint and demonstrated an overall favorable safety and tolerability profile. ApolloBio plans to use the results from the study to support a future regulatory submission of VGX-3100 in China.\"We believe these positive topline results for VGX-3100 reflect both the potential of our DNA medicine platform in HPV-related diseases and the power of partnerships to advance innovative DNA immunotherapies,\" said Dr. Jacqueline Shea, INOVIO's President and Chief Executive Officer. \"We look forward to these data being presented at upcoming international medical conferences and published in peer-reviewed publications. We also anticipate future updates from ApolloBio as they work towards filing for potential regulatory approval of VGX-3100 in China.\"According to the terms of the ApolloBio Agreement, INOVIO is entitled to receive up to an aggregate of $20.0 million, less required income, withholding or other taxes, upon the achievement of specified milestones related to the regulatory approval of VGX-3100 in specified territories. In the event that VGX-3100 is approved for marketing, INOVIO will be entitled to receive royalty payments based on a tiered percentage of annual net sales.About VGX-3100VGX-3100 is an innovative therapeutic DNA vaccine developed for diseases associated with high-risk human papillomavirus (HPV) types 16 and 18. VGX-3100 is designed to elicit an antigen-specific, CD...